Coordinatore | UNIVERSITA DEGLI STUDI DI VERONA
Organization address
address: VIA DELL ARTIGLIERE 8 contact info |
Nazionalità Coordinatore | Italy [IT] |
Sito del progetto | http://rpc.spsichiatria.univr.it/refinementproject/ |
Totale costo | 3˙816˙043 € |
EC contributo | 2˙999˙195 € |
Programma | FP7-HEALTH
Specific Programme "Cooperation": Health |
Code Call | FP7-HEALTH-2010-single-stage |
Funding Scheme | CP-FP |
Anno di inizio | 2011 |
Periodo (anno-mese-giorno) | 2011-01-01 - 2013-12-31 |
# | ||||
---|---|---|---|---|
1 |
UNIVERSITA DEGLI STUDI DI VERONA
Organization address
address: VIA DELL ARTIGLIERE 8 contact info |
IT (VERONA) | coordinator | 889˙974.20 |
2 |
LUDWIG BOLTZMANN GESELLSCHAFT OSTERREICHISCHE VEREINIGUNG ZUR FORDERUNG DER WISSENSCHAFTLICHEN FORSCHUNG
Organization address
address: NUSSDORFER STRASSE 64/6 contact info |
AT (WIEN) | participant | 448˙700.00 |
3 |
LONDON SCHOOL OF ECONOMICS AND POLITICAL SCIENCE
Organization address
address: Houghton Street 1 contact info |
UK (LONDON) | participant | 444˙189.20 |
4 |
STIFTELSEN SINTEF
Organization address
address: Strindveien 4 contact info |
NO (TRONDHEIM) | participant | 390˙136.50 |
5 |
TERVEYDEN JA HYVINVOINNIN LAITOS
Organization address
address: MANNERHEIMINTIE 166 contact info |
FI (HELSINKI) | participant | 249˙440.25 |
6 |
ASOCIACION CIENTIFCA PSICOST
Organization address
address: CALLE ENERGIA SOLAR BLOQUE G 1 contact info |
ES (SEVILLA) | participant | 241˙317.60 |
7 |
UNIVERSITE PARIS XII VAL DE MARNE
Organization address
address: AVENUE DU GENERAL DE GAULLE 61 contact info |
FR (CRETEIL) | participant | 139˙292.00 |
8 |
ROMANIAN ACADEMY NATIONAL INSTITUTE FOR ECONOMIC RESEARCH
Organization address
address: 13 Calea 13 Septembrie contact info |
RO (BUCHAREST) | participant | 127˙080.00 |
9 |
TARTU ULIKOOL
Organization address
address: ULIKOOLI 18 contact info |
EE (TARTU) | participant | 69˙065.81 |
Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.
'REFINEMENT will conduct the first ever comparative and comprehensive overview of links between the financing of mental health care in Europe and the outcomes of mental health services. Mental health is a key priority area for Europe, as evidenced by the publication by the European Commission in June 2008 of its European Pact on Mental Health and Wellbeing. Conducted across nine European Countries (Italy, Austria, UK, Spain, Finland, Norway, France, Estonia and Romania) it will bring together an experienced team of health economists, mental health service researchers, public health specialists and cover, in term of funding models and interfaces with social care services, a representative range of health care systems across Europe. Four core scientific objectives of REFINEMENT will help us attain our overarching goal of determining how variations in the structure and characteristics of mental health financing systems in nine European states: (1) impact on quality of care; (2) impact on the appropriateness of pathways through the services system; (3) help identify best practice and effective innovations and components of the financing system; and (4) allow us to draw conclusions and present recommendations on how best to structure funding systems in different country contexts. The first objective is to map and describe characteristics (including incentives) of financing systems for mental health care. In objective 2 using detailed descriptions of nine mental health systems, we wish to describe the outcomes of mental health services, including quality of care and met/unmet needs. Objective 3 will describe typical pathways through the health and social care system by people with mental health needs. Finally objective 4 is to build a series of health care financing models conducive to the promotion of high quality mental health care associated with better outcomes, drawing on data obtained as part of the three previous objectives.'
Examining ways to enhance systems of finance and performance assessment in mental health care across the EU sheds light on best practices.
Unraveling the molecular mechanism of nitrosative stress resistance in tuberculosis
Read More"Transposon-based, targeted ex vivo gene therapy to treat age-related macular degeneration (AMD)"
Read MoreVector-borne Risks for Europe: Risk assessment and control of West Nile and Chikungunya virus (VECTORIE)
Read More